Y Intercept Hong Kong Ltd Has $2.42 Million Stock Holdings in Becton, Dickinson and Company $BDX

Y Intercept Hong Kong Ltd reduced its holdings in Becton, Dickinson and Company (NYSE:BDX) by 52.8% during the 3rd quarter, Holdings Channel reports. The fund owned 12,911 shares of the medical instruments supplier’s stock after selling 14,445 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Becton, Dickinson and Company were worth $2,417,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in Becton, Dickinson and Company by 15.4% during the 2nd quarter. Vanguard Group Inc. now owns 32,308,749 shares of the medical instruments supplier’s stock worth $5,565,182,000 after buying an additional 4,305,947 shares in the last quarter. Norges Bank acquired a new stake in shares of Becton, Dickinson and Company during the second quarter worth $653,377,000. First Eagle Investment Management LLC boosted its holdings in Becton, Dickinson and Company by 59.2% during the second quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock worth $1,513,421,000 after buying an additional 3,268,478 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Becton, Dickinson and Company by 24.4% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 8,514,446 shares of the medical instruments supplier’s stock worth $1,466,613,000 after buying an additional 1,670,590 shares during the period. Finally, Laurel Wealth Advisors LLC raised its position in shares of Becton, Dickinson and Company by 16,974.4% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 1,579,386 shares of the medical instruments supplier’s stock valued at $272,049,000 after acquiring an additional 1,570,136 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on BDX. Morgan Stanley upped their target price on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Jefferies Financial Group boosted their price target on Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, December 10th. Royal Bank Of Canada raised their target price on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a research report on Wednesday, December 17th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Finally, Wall Street Zen downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Four equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $209.00.

Becton, Dickinson and Company News Roundup

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Board declared a quarterly dividend of $1.05 per share (payable March 31; record date March 10), implying a ~2.1% yield — supports income investors and signals cash‑flow confidence. BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $250 Million Repurchase to Date in FY26
• Positive Sentiment: Board authorized an additional $10M share buyback and the company says it has completed ~$250M of repurchases in FY26 to date — modest on a large market cap but signals management sees shareholder value in buybacks. RTT News – Stock Buybacks
• Positive Sentiment: Spin‑off of BD’s Biosciences & Diagnostic Solutions business is advancing: company set a February 5 record date and Waters shareholders approved the combination — this corporate‑restructuring could unlock value and reshape BD’s growth profile. BD Announces Record Date for the Spin-Off
• Positive Sentiment: Waters shareholders approved the combination with BD’s biosciences unit, removing a key approval hurdle and making the transaction timing clearer for investors. Waters Shareholders Approve Combination
• Positive Sentiment: Product and tech update — BD launched BD Research Cloud 7.0 with an AI-powered Horizon Panel Maker for advanced flow cytometry, supporting differentiation in lab workflow automation and data analytics. BDX Introduces BD Research Cloud 7.0
• Neutral Sentiment: BD scheduled an audio webcast to announce Q1 FY2026 results — earnings and guidance will be the next major catalyst and could increase volatility. BD to Announce Financial Results for its First Quarter of Fiscal 2026
• Neutral Sentiment: Several analyst/feature pieces highlight BDX as a value and momentum name and compare it to peers — useful for sentiment but not new company fundamentals. Why Becton Dickinson (BDX) is a top value stock

Becton, Dickinson and Company Stock Performance

NYSE BDX traded up $0.96 during trading on Wednesday, reaching $204.36. The company’s stock had a trading volume of 102,938 shares, compared to its average volume of 1,676,365. The firm has a 50 day moving average price of $197.87 and a 200 day moving average price of $190.90. Becton, Dickinson and Company has a 12 month low of $162.29 and a 12 month high of $251.99. The firm has a market capitalization of $58.22 billion, a price-to-earnings ratio of 35.06, a price-to-earnings-growth ratio of 2.25 and a beta of 0.23. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. The firm had revenue of $5.89 billion for the quarter, compared to analyst estimates of $5.91 billion. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The company’s revenue was up 8.3% on a year-over-year basis. During the same quarter last year, the company earned $3.81 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 72.04%.

Becton, Dickinson and Company announced that its Board of Directors has approved a stock repurchase program on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the transaction, the director owned 35,816 shares in the company, valued at approximately $6,324,389.28. This trade represents a 0.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 2,605 shares of company stock worth $524,643. 0.40% of the stock is currently owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.